BTG’s string-of-beads tempts Boston Scientific to shell out £3.3bn ($4.2bn) for the UK company.
Novo Nordisk is determined to dominate obesity, but two discontinuations hint that the ride might be rocky.
The company hails a partial clinical trial win as the way in to a new use for Hetlioz, but the stock markets are less convinced.
Voxeleron is, like Google’s related company Deepmind, using artificial intelligence to analyse ocular images. Unlike Deepmind, it is employing a targeted approach.
The industry has its work cut out to rebuild trust in the tech following doubts about one pioneer, IBM Watson.
Full results of the Mystic study present a controversial path forward for Imfinzi, and set the stage for the upcoming Neptune trial to be overhauled.
It could be hard for Macrogenics to shake off new safety concerns, whether it is the DART bispecific construct or its protein target that is to blame.
Verona Pharma needs another COPD win, while Alexion seeks a new use for its Soliris successor.
Lilly reduces its reliance on older products, but Roche and Sanofi still need fresh blood.
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…